Withdrawn Drugs

·         Phenformin: lactic acidosis

·         Troglitazone: hepatotoxicity.

·         Terfenadine: CYP3A4 inhibition caused ventricular tachycardia.

·         fenfluramine and dexfenfluramine: cardiac toxicity.

·         Zimelidine (1^st SSRI) was withdrawn due to an association with febrile illness and Guillain-Barre ascending paralysis.

·         Nomifensine is a structurally distinct antidepressant that inhibits the transport of both norepinephrine and dopamine; it was withdrawn from clinical use in 1996 owing to risk of hemolytic anemia and intravascular hemolysis.

·         Rofecoxib: GI bleed

·         Bromfenac(NSAAID) - its association with severe, irreversible liver injury

·         Milrinone :increase in sudden cardiac death

·         Phenolphthalein, once among the most popular components of laxatives, has been withdrawn from the market in the United States because of potential carcinogenicity. Oxyphenisatin, another older drug, was withdrawn due to hepatotoxicity.

·         alosetron was withdrawn from the U.S. market because of an unusually high incidence of ischemic colitis

·         The CYP2D6 polymorphism has led to the withdrawal of several clinically used drugs (e.g., debrisoquine and perhexiline) and the cautious use of others that are known CYP2D6 substrates (e.g., encainide and flecainide  [antiarrhythmics], desipramine and nortriptyline  [antidepressants], and codeine).